http://pharmaweblog.com/blog/2006/03/27/anormed-elevates-public-fight-with-dissident-board-member/ Pharmaceutical and biotech science and business Wed, 20 Aug 2008 10:43:57 +0000 http://wordpress.org/?v=2.0.2 http://pharmaweblog.com/blog/2006/03/27/anormed-elevates-public-fight-with-dissident-board-member/#comment-18 Tue, 05 Sep 2006 13:33:40 +0000 http://pharmaweblog.com/blog/2006/03/27/anormed-elevates-public-fight-with-dissident-board-member/#comment-18 [...] Genzyme to Make Offer for AnorMed - New York Times describes Genzyme’s attempt to make an unsolicited (i.e. hostile) tender offer for all outstanding shares in Candian biotech Anormed, developers of Mozobil.  Regular readers will recall my detailed account of the recent overthrow of AnorMed’s CEO and board by Baker Brothers, a hedge fund.  In that account I noted that the larger lesson was that should hedge funds increasingly play an active role in biotech financing, expect them to play an active role in biotech management.    [...] […] Genzyme to Make Offer for AnorMed - New York Times describes Genzyme’s attempt to make an unsolicited (i.e. hostile) tender offer for all outstanding shares in Candian biotech Anormed, developers of Mozobil.  Regular readers will recall my detailed account of the recent overthrow of AnorMed’s CEO and board by Baker Brothers, a hedge fund.  In that account I noted that the larger lesson was that should hedge funds increasingly play an active role in biotech financing, expect them to play an active role in biotech management.    […]

]]>